nach oben

vorheriger Artikel Differential diagnosis of neovascular age-relat...

nächster Artikel Vitreous and macular hole: genesis and nemesis

Tipp

Pharmacologic vitreolysis for vitreomacular traction syndrome and macular hole

From clinical trials to clinical practice

Zeitschrift:: Spektrum der Augenheilkunde > Ausgabe 1/2018

Autoren:: Dr. Kleanthis Manousaridis, Silvia Peter-Reichart, Stefan Mennel

» Jetzt Zugang zum Volltext erhalten

Summary

Pharmacologic vitreolysis with ocriplasmin has emerged as a new option for the treatment of symptomatic vitreomacular traction syndrome (VMT). Not all cases of VMT require therapy. Knowledge of the natural history of VMT is essential for patient counselling and for deciding between observation and treatment. Ocriplasmin treatment for VMT may provide very good results if used with the correct candidates. On the other hand, observation might be the best option in cases of VMT with high chances of spontaneous resolution. The purpose of this review is to report on the natural course of VMT based on the current literature, present briefly the author’s experience with the use of ocriplasmin in cases of VMT, and provide practical hints for the implementation of this treatment modality in the clinical setting.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Jetzt einloggen Kostenlos registrieren

Duker JS, Kaiser PK, Binder S, et al. The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology. 2013;120:2611–9. CrossRefPubMed

Stalmans P, Benz MS, Gandorfer A et al. MIVI-TRUST Study Group.. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med. 2012;367:606–15. CrossRefPubMed

Stalmans P, Duker JS, Kaiser PK, et al. Obased interpretation of the vitreomacular interface and indications for pharmacologic vitreolysis. Retina. 2013;33:2003–11. CrossRefPubMed

Jackson TL, Nicod E, Angelis A, et al. Pars plana vitrectomy for vitreomacular traction syndrome: a systematic review and metaanalysis of safety and efficacy. Retina. 2013;33:2012–7. CrossRefPubMed

Lee SW, Kang SW, Kim YT, et al. Vitreous surgery for impending macular hole. Retina. 2011;31:909–14. CrossRefPubMed

Jost BF, Hutton WL, Fuller DG, et al. Vitrectomy in eyes at risk for macular hole formation. Ophthalmology. 1990;97:843–7. CrossRefPubMed

Hikichi T, Yoshida A, Trempe CL. Course of vitreomacular traction syndrome. Am J Ophthalmol. 1995;119:55–61. CrossRefPubMed

John VJ, Flynn HW Jr, Smiddy WE, et al. Clinical course of vitreomacular adhesion managed by initial observation. Retina. 2014;34:442–6. CrossRefPubMed

Wu L, Zas M, Berrocal MH, Arevalo JF, et al. Anatomical and functional outcomes of symptomatic idiopathic vitreomacular traction: a natural history study from the Pan American Collaborative Retina Study Group. Retina. 2016;36:1913–8. CrossRefPubMed

10.

Almeida DR, Chin EK, Rahim K, et al. Factors associated with spontaneous release of vitreomacular traction. Retina. 2015;35:492–7. CrossRefPubMed

11.

Theodossiadis GP, Chatziralli IP, Sergentanis TN, et al. Evolution of vitreomacular adhesion to acute vitreofoveal separation with special emphasis on a traction-induced foveal pathology. A prospective study of spectral-domain optical coherence tomography. Graefes Arch Clin Exp Ophthalmol. 2015;253:1425–35. CrossRefPubMed

12.

Theodossiadis GP, Grigoropoulos VG, Theodoropoulou S, et al. Spontaneous resolution of vitreomacular traction demonstrated by spectral-domain optical coherence tomography. Am J Ophthalmol. 2014;157:842–51. CrossRefPubMed

13.

Tzu JH, John VJ, Flynn HW Jr, et al. Clinical course of vitreomacular traction managed initially by observation. Ophthalmic Surg Lasers Imaging Retina. 2015;46:571–6. CrossRefPubMed

14.

Odrobina D, Michalewska Z, Michalewski J, et al. Long-term evaluation of vitreomacular traction disorder in spectral-domain optical coherence tomography. Retina. 2011;31:324–31. CrossRefPubMed

15.

Charalampidou S, Nolan J, Beatty S. The natural history of tractional cystoid macular edema. Retina. 2012;32:2045–51. CrossRefPubMed

16.

Ziemssen F, Bartz-Schmidt KU, Dimopoulos S. Knowledge of vitreomacular traction (VMT) scenarios: is doing nothing still a beneficial alternative and, if so, when? Graefes Arch Clin Exp Ophthalmol. 2016;254:615–6. CrossRefPubMed

17.

Paul C, Heun C, Müller HH, et al. Impact of vitreoretinal interface architecture on successful vitreomacular traction resolution in eyes scheduled for intravitreal ocriplasmin therapy. Retina. 2017;37(7):1252–60. https://doi.org/10.1097/IAE.0000000000001371. CrossRefPubMed

18.

Singh RP, Li A, Bedi R, Srivastava S, et al. Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome. Br J Ophthalmol. 2014;98:356–60. CrossRefPubMed

19.

Maier M, Abraham S, Frank C, et al. Therapie der vitreomakulären Traktion mit und ohne Makulaforamen. Klin Monbl Augenheilkd. 2016;233:622–30. CrossRefPubMed

20.

Lommatzsch AP, Gutfleisch M, Dietzel M, et al. Erste klinische Erfahrungen bei der Behandlung von vitreomakulären Traktionen mit Ocriplasmin. Klin Monbl Augenheilkd. 2014;231:909–14. CrossRefPubMed

21.

Mennel S. Enzymatic vitreolysis – from clinical trials to clinical practice. Spektrum Augenheilkd. 2014;28:59–60.

22.

Manousaridis K, Peter-Reichart S, Mennel S. Ocriplasmin treatment for vitreomacular traction in real life: can the indication spectrum be expanded? Graefes Arch Clin Exp Ophthalmol. 2017; https://doi.org/10.1007/s00417-017-3731-9. PubMed

23.

Bertelmann T, Wachtlin J, Mennel S, et al. The predictability of ocriplasmin treatment effects: is there consensus among retinal experts? Results from the EXPORT study. Graefes Arch Clin Exp Ophthalmol. 2017; https://doi.org/10.1007/s00417-017-3657-2.

24.

Krishnan R, Arora R, De Salvo G, et al. Vitreomacular traction affects anti-vascular endothelial growth factor treatment outcomes for exudative age-related macular degeneration. Retina. 2015;35:1750–6. CrossRefPubMed

25.

Mennel S, Meyer CH, Schmidt JC. Der Einfluss des Glaskörpers auf die Pathogenese der altersabhängigen Makuladegeneration. Klin Monbl Augenheilkd. 2011;228:460–4. CrossRefPubMed

26.

Diabetic Retinopathy Clinical Research Network Writing Committee, Haller JA, Qin H, Apte RS, et al. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology. 2010;117:1087–93. CrossRef

27.

Novack RL, Staurenghi G, Girach A, et al. Safety of intravitreal ocriplasmin for focal vitreomacular adhesion in patients with exudative age-related macular degeneration. Ophthalmology. 2015;122:796–802. CrossRefPubMed

28.

Kaiser PK, Kampik A, Kuppermann BD, et al. Safety profile of ocriplasmin for the pharmacologic treatment of symptomatic vitreomacular adhesion/traction. Retina. 2015;35:1111–27. CrossRefPubMed

Titel: Pharmacologic vitreolysis for vitreomacular traction syndrome and macular hole
From clinical trials to clinical practice
Autoren:: Dr. Kleanthis Manousaridis
Silvia Peter-Reichart
Stefan Mennel
Publikationsdatum: 15.12.2017
DOI: https://doi.org/10.1007/s00717-017-0385-2
Verlag: Springer Vienna
Zeitschrift: Spektrum der Augenheilkunde
Ausgabe 1/2018
Print ISSN: 0930-4282
Elektronische ISSN: 1613-7523

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Hybrid 20/23-gauge vitrectomy in a patient with retained intraocular air-gun pellet

Intravitreal Actilyse® injection to induce posterior vitreous detachment in eyes with recent onset of retinal vein occlusion

Vitreous and macular hole: genesis and nemesis

Differential diagnosis of neovascular age-related macular degeneration

Autosomal-dominante Optikusatrophie

Harvey Alan Lincoff, M. D.